Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Active Disease, ICU Deferral Linked With COVID-19–Related Mortality in AML, ALL, and MDS
Mortality rates in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were higher compared with non-cancer populations who were infected with the virus.
Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL
The combination of tafasitamab and lenalidomide prolonged median overall survival compared with other standard options for autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.
Strong Antibody Response to mRNA COVID-19 Vaccine Observed in AML, MDS
An observational single-center study suggests that mRNA-1273 SARS CoV-2 vaccination induces a strong antibody response in patients with acute myeloid leukemia and myelodysplastic syndrome, according to observational results presented during the 2021 ASH Annual Meeting.
Daratumumab Plus VTd Enhances MRD-Negativity Rates in Transplant-Eligible Myeloma
December 11th 2021Minimal residual disease–negativity rates were significantly higher after utilizing daratumumab plus bortezomib, thalidomide, and dexamethasone (VTd) vs VTd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the phase 3 CASSIOPEIA study that were presented at the 2021 ASH Annual Meeting and Exposition.
Subcutaneous Daratumumab Plus SOC Maintains Efficacy in Newly Diagnosed AL Amyloidosis
December 11th 2021The addition of subcutaneous daratumumab to standard-of-care bortezomib, cyclophosphamide, and dexamethasone (D-VCd) continued to elicit stronger hematologic and organ responses vs VCd alone in patients with newly diagnosed light chain amyloidosis.
Isatuximab Plus RVd Improves MRD Negativity Rates in Transplant-Eligible, Newly Diagnosed Myeloma
The addition of isatuximab to lenalidomide, bortezomib, and dexamethasone (RVd) demonstrated superior minimal residual disease rates vs RVd alone when used as induction treatment in patients with transplant-eligible newly diagnosed multiple myeloma.
Tisagenlecleucel Displays Promising Efficacy Results Across Subgroups in R/R FL
Tisagenlecleucel produced a high overall response rate and complete response rate in adult patients with relapsed/refractory follicular lymphoma who had received 2 or more prior lines of therapy, according to results from an extended follow-up analysis of patients with at least 12 months of follow-up of the phase 2 ELARA trial.
Axi-Cel Demonstrates Ongoing Survival Benefit in Relapsed/Refractory iNHL
Axicabtagene ciloleucel induced high response rates and improved survival in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma, according to updated data from the phase 2 ZUMA-5 trial.
Parsaclisib Elicits Lasting Responses in Relapsed/Refractory Marginal Zone Lymphoma
Parsaclisib demonstrated early and long-lasting responses in patients with BTK-naïve, relapsed/refractory marginal zone lymphoma, according to findings from the phase 2 CITADEL-204 trial.
Frontline Venetoclax-Based Combos Improve uMRD Rates Vs Chemoimmunotherapy in Fit Patients With CLL
December 11th 2021The combination of obinutuzumab and venetoclax (GVe), as well as GVe plus ibrutinib demonstrated superior rates of undetectable minimal residual disease compared with chemoimmunotherapy in fit patients with chronic lymphocytic leukemia, according to findings from the phase 3 GAIA (CLL13) trial.
Orca-T Shows Impressive Clinical Outcomes in High-Risk Hematological Cancers
Orca-T significantly improved graft-vs-host disease–free relapse-free survival and time to engraftment, significantly reduced acute and chronic GVHD, and showed a trend toward improved overall survival vs standard of care in patients with serious hematologic malignancies
Fixed-duration treatment with the bispecific antibody mosunetuzumab induced deep and durable responses with favorable tolerability in heavily pretreated patients with relapsed or refractory follicular lymphoma, meeting the primary end point of the ongoing phase 1/2b GO29781 trial.
Liso-cel Bests Standard of Care in Second-Line Treatment of LBCL
Lisocabtagene maraleucel demonstrated statistically and clinically meaningful improvement in event-free survival compared with the standard of care as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma.
Neratinib Combos Show Promise in HER2-Mutant Metastatic Breast Cancers
Neratinib (Nerlynx) induced positive overall response rates in patients with heavily pretreated hormone receptor–positive/HER2-negative, HER2-mutant metastatic breast cancer when combined with fulvestrant and trastuzumab, and also in patients with metastatic HER2-mutant triple-negative breast cancer when combined with trastuzumab.
AEs Related to Olaparib Treatment May Be Easily Mitigated in High-Risk Early Breast Cancer
December 10th 2021Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with germline BRCA1/2 mutations in patients with high-risk, HER2-negative, early-stage breast cancer.
Samuraciclib Plus Fulvestrant Improves PFS in Heavily Pretreated HR+ Breast Cancer
Fulvestrant plus the CDK7 inhibitor samuraciclib demonstrated encouraging efficacy in patients with hormone receptor-positive breast cancer who were heavily pretreated with CDK4/6 inhibitors.
